Authorized purpose: Radiological computer-aided triage and notification for chest CTA suspected pulmonary embolism and chest or thoraco-abdominal CTA suspected aortic dissection, assisting hospital networks and trained radiologists with workflow prioritization in parallel with standard-of-care interpretation.
Clinical role
Parallel triage and notification support; it does not alter the original image or provide a diagnostic result beyond notification, and clinicians remain responsible for full-image review.
Images and patients
CT/CTA · Chest and thoraco-abdominal aorta
Key limitation
Keep in mind: Notifications and compressed previews are informational and not for diagnosis; the device is not intended as a diagnostic device or to replace standard-of-care full-image interpretation. PE and AD are separate applications and performance endpoints.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Radiological computer-aided triage and notification for chest CTA suspected pulmonary embolism and chest or thoraco-abdominal CTA suspected aortic dissection, assisting hospital networks and trained radiologists with workflow prioritization in parallel with standard-of-care interpretation.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Chest and thoraco-abdominal aorta Input: Chest CTA for suspected PE and chest or thoraco-abdominal CTA for suspected AD, received as DICOM images through the CINA Platform or a compatible medical-image communications device.
Who uses it?Intended users: Hospital networks and trained radiologists; notified clinicians review full images under standard of care.
What does the software produce?Output: Worklist pop-up and passive icon notifications identifying suspected PE or AD, with patient name, accession number, finding type, and a compressed preview labeled not for diagnostic use; output files can be transferred to PACS or a workstation.
What is its most important limitation?Key limitation: Notifications and compressed previews are informational and not for diagnosis; the device is not intended as a diagnostic device or to replace standard-of-care full-image interpretation. PE and AD are separate applications and performance endpoints.
Clinical takeaway. Clinical role: Radiological computer-aided triage and notification for chest CTA suspected pulmonary embolism and chest or thoraco-abdominal CTA suspected aortic dissection, assisting hospital networks and trained radiologists with workflow prioritization in parallel with standard-of-care interpretation.
Evidence takeaway. Evidence from the reviewed source record: A retrospective multicenter blinded study included 396 PE cases from 230 U.S. cities/sites as stated in the packet and 298 AD cases from 200, with 190 positive PE and 137 positive AD cases; ground truth used concurrence of several U.S.-board-certified radiologists. PE sensitivity/specificity were 91.1% (95% CI 86.1%-94.7%) and 91.8% (87.1%-95.1%); AD sensitivity/specificity were 96.4% (91.7%-98.8%) and 97.5% (93.8%-99.3%). Overall agreement was 91.4% for PE and 97% for AD, MCC was 0.83 and 0.94, and mean time-to-notification was 63 seconds for PE and 36.5 seconds for AD. These are separate condition-specific sensitivity/specificity, agreement, correlation, and latency endpoints.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Radiological computer-aided triage and notification for chest CTA suspected pulmonary embolism and chest or thoraco-abdominal CTA suspected aortic dissection, assisting hospital networks and trained radiologists with workflow prioritization in parallel with standard-of-care interpretation.
Parallel triage and notification support; it does not alter the original image or provide a diagnostic result beyond notification, and clinicians remain responsible for full-image review.
Chest CTA for suspected PE and chest or thoraco-abdominal CTA for suspected AD, received as DICOM images through the CINA Platform or a compatible medical-image communications device.
Worklist pop-up and passive icon notifications identifying suspected PE or AD, with patient name, accession number, finding type, and a compressed preview labeled not for diagnostic use; output files can be transferred to PACS or a workstation.
Notifications and compressed previews are informational and not for diagnosis; the device is not intended as a diagnostic device or to replace standard-of-care full-image interpretation. PE and AD are separate applications and performance endpoints.
A retrospective multicenter blinded study included 396 PE cases from 230 U.S. cities/sites as stated in the packet and 298 AD cases from 200, with 190 positive PE and 137 positive AD cases; ground truth used concurrence of several U.S.-board-certified radiologists. PE sensitivity/specificity were 91.1% (95% CI 86.1%-94.7%) and 91.8% (87.1%-95.1%); AD sensitivity/specificity were 96.4% (91.7%-98.8%) and 97.5% (93.8%-99.3%). Overall agreement was 91.4% for PE and 97% for AD, MCC was 0.83 and 0.94, and mean time-to-notification was 63 seconds for PE and 36.5 seconds for AD. These are separate condition-specific sensitivity/specificity, agreement, correlation, and latency endpoints.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
A retrospective multicenter blinded study included 396 PE cases from 230 U.S. cities/sites as stated in the packet and 298 AD cases from 200, with 190 positive PE and 137 positive AD cases; ground truth used concurrence of several U.S.-board-certified radiologists. PE sensitivity/specificity were 91.1% (95% CI 86.1%-94.7%) and 91.8% (87.1%-95.1%); AD sensitivity/specificity were 96.4% (91.7%-98.8%) and 97.5% (93.8%-99.3%). Overall agreement was 91.4% for PE and 97% for AD, MCC was 0.83 and 0.94, and mean time-to-notification was 63 seconds for PE and 36.5 seconds for AD. These are separate condition-specific sensitivity/specificity, agreement, correlation, and latency endpoints.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
CINA CHEST-PE regulatory performance study summary
DesignStand-Alone Performance
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K210237
Samplen=396
Sites230
IndependenceIndependence not established
K210237
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K210237. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Chest CTA for suspected PE and chest or thoraco-abdominal CTA for suspected AD, received as DICOM images through the CINA Platform or a compatible medical-image communications device.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The packet describes an on-premise Worklist Application, standardized DICOM communication with CT modalities and other DICOM nodes such as routers or PACS, and output to PACS/workstations; exact local interface versions are not established.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes CINA CHEST as running on a standard off-the-shelf server/workstation, with its image processing applications integrated, deployed and used with the CINA Platform reference device or other compatible medical image communications devices. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "CINA CHEST runs on a standard “off the shelf” server/workstation and is comprised of PE and AD Image Processing Applications" … "which can be integrated, deployed and used with the reference device (K200855) or other compatible medical image communications devices.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Worklist pop-up and passive icon notifications identifying suspected PE or AD, with patient name, accession number, finding type, and a compressed preview labeled not for diagnostic use; output files can be transferred to PACS or a workstation.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Worklist pop-up and passive icon notifications identifying suspected PE or AD, with patient name, accession number, finding type, and a compressed preview labeled not for diagnostic use; output files can be transferred to PACS or a workstation.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes CINA CHEST as running on a standard off-the-shelf server/workstation, with its image processing applications integrated, deployed and used with the CINA Platform reference device or other compatible medical image communications devices. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "CINA CHEST runs on a standard “off the shelf” server/workstation and is comprised of PE and AD Image Processing Applications" … "which can be integrated, deployed and used with the reference device (K200855) or other compatible medical image communications devices.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The packet describes an on-premise Worklist Application, standardized DICOM communication with CT modalities and other DICOM nodes such as routers or PACS, and output to PACS/workstations; exact local interface versions are not established.
Avicenna.AI's cybersecurity page states ISO/IEC 27001 certification by SGS, IEC 81001-5-1, TLS 1.2+ in transit, encryption at rest, role-based access with least privilege, and a HIPAA business associate agreement for US customers. Vendor-wide.
Vendor-wide
Checked 2026-10-25
Vendor statement, not an attestation; exact-release scope is not established.
ACR AI Central provides an exact-submission model card for CINA CHEST; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
25Fields reviewed
10Source classes checked
1Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate record. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K210237 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-09 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: BriefCase is a radiological computer aided triage and notification software indicated for use in the analysis of CTPA images in adults or transitional adolescents aged 18 and older. The device is intended to assist hospital networks and appropriately trained medical specialists in workflow triage by flagging and communication of suspected positive findings of Pulmonary Embolism (PE) pathologies. Briefcase uses an artificial intelligence algorithm to analyze images and highlight cases with detected findings on a Stand-Alone Performance desktop application in parallel to the ongoing standard of care image interpretation. The user is presented with notifications for cases with suspected PE findings. Notifications include compressed preview images that are meant for informational purposes only and not intended for diagnostic use beyond notification. The device does not alter the original medical image and is not intended to be used as a diagnostic device. The results of BriefCase are intended to be used in conjunction with other patient information and based on their professional judgment, to assist with triage/prioritization of medical images. Notified clinicians are responsible for viewing full images per the standard of care.
Authorized purpose: Passive workflow prioritization for studies with imaging patterns consistent with possible total arterial occlusion in the specified vessels; not primary diagnosis, screening, disease detection, or patient-management decision support
Modality
CT/CTA
Anatomy
Aorta and lower-extremity arteries: common iliac, external iliac, common femoral, superficial femoral, and popliteal arteries
Authorized purpose: Parallel-workflow triage and notification of suspected incidental pulmonary embolism on contrast-enhanced images that include the lungs.
Authorized purpose: Assist hospital networks and appropriately trained physician specialists by flagging suspected acute cervical-spine fractures on cervical-spine CT for triage and prioritization; it is not designed to detect vertebral compression fractures.
Modality
CT/CTA
Anatomy
Cervical spine; acute cervical-spine fractures including non-displaced lines and displaced fragments
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.